ORGO (Organogenesis Holdings) Tariff Resilience Score: 7/10 (As of Jul. 05, 2026)


ORGO Organogenesis Holdings Inc ORGO
67 GF Score
Price $2.36
GF Value $3.10
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings Tariff Resilience Score?

Organogenesis Holdings ORGO -3.08% 67 Tariff Resilience Score is 7 as of Jul. 05, 2026. GuruFocus rates ORGO with a GF Score™ of 67/100 and a GF Value™ of $3.10 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Organogenesis Holdings ranks better than 97.09% on this metric.

Organogenesis Holdings has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Organogenesis Holdings has Biotech company with a focus on regenerative medicine. Limited exposure to tariffs due to domestic manufacturing and sales. Some vulnerability in sourcing specialized materials internationally.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Organogenesis Holdings might have Highly Resilient.

Organogenesis Holdings  (NAS:ORGO) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Organogenesis Holdings Tariff Resilience Score Related Terms

ORGO vs TKNO, AKBA, SIGA: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Organogenesis Holdings Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Tariff Resilience Score falls into.


ORGO
67GF Score
Organogenesis Holdings Inc ORGO
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Organogenesis Holdings (ORGO) has a Tariff Resilience Score of 7 as of Jul. 05, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Organogenesis Holdings ranks #30 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Organogenesis Holdings' Tariff Resilience Score too high?
Organogenesis Holdings' current Tariff Resilience Score is 7. Based on the distribution chart, Organogenesis Holdings ranks #30 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Tariff Resilience Score compare to TKNO and AKBA?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #30 out of 1030 companies for Tariff Resilience Score. This places Organogenesis Holdings in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Organogenesis Holdings's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (ORGO) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.10, compared to a current price of $2.36 — trading 23.9% below its estimated fair value. The current Tariff Resilience Score is 7. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Organogenesis Holdings (ORGO), the current Tariff Resilience Score is 7 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (ORGO) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of $2.36 is trading 23.9% below its estimated GF Value™ of $3.10. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for ORGO:

  • Tariff Resilience Score: 7
  • GF Value™: $3.10 vs. price of $2.36 (23.9% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ORGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organogenesis Holdings Business Description

Other Exchanges 2PQ:Germany
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score

Get the complete analysis for ORGO

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.36
Price
$3.10
GF Value